Product image of Olmesartan Plus Hct Eg (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Olmesartan Plus Hct Eg

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Olmesartan Plus Hct Eg (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Plus Hct Eg, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and is combined with a thiazide diuretic to enhance antihypertensive effect in adult patients.

GNH India supplies Olmesartan Plus Hct Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Plus Hct Eg is used to manage hypertension, acting on the renin‑angiotensin‑aldosterone system to lower systemic blood pressure.

  • Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
  • Hypertension with fluid retention: provides additional diuretic effect to control edema.
  • Hypertension requiring combination therapy: simplifies treatment by combining an ARB with a thiazide diuretic.

How It Works

  • Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal glands, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, promoting diuresis. The combined actions lower peripheral vascular resistance and plasma volume, resulting in a sustained reduction of arterial blood pressure.

Side Effects

Common and serious adverse reactions have been reported with Olmesartan Plus Hct Eg.

Common Side Effects

  • Dizziness: transient light‑headedness, especially after initial dosing.
  • Headache: mild to moderate cranial pain.
  • Fatigue: general feeling of tiredness.
  • Increased urination: due to the thiazide component.

Serious or Rare Side Effects

  • Angioedema: swelling of face, lips, tongue, or airway.
  • Severe dehydration: excessive fluid loss leading to low blood pressure.
  • Acute kidney injury: sudden decline in renal function.
  • Hyperkalemia: elevated blood potassium levels.

Precautions & Warnings

Before prescribing Olmesartan Plus Hct Eg, clinicians should consider several safety precautions.

  • Renal function monitoring: assess serum creatinine and eGFR regularly.
  • Electrolyte balance: check potassium and sodium levels due to thiazide effect.
  • Pregnancy avoidance: contraindicated in the second and third trimesters.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Gradual discontinuation: avoid abrupt cessation to prevent rebound hypertension.
  • Store at room temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Olmesartan Plus Hct Eg may interact with other medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid)

  • Aliskiren (in diabetic patients): increased risk of renal impairment.
  • Potassium‑sparing diuretics: risk of hyperkalemia.
  • ACE inhibitors or other ARBs: additive effect on potassium and blood pressure.
  • Lithium: increased lithium toxicity.
  • NSAIDs (high dose): may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely)

  • Other thiazide diuretics: additive diuretic effect, monitor electrolytes.
  • Antihypertensive agents (beta‑blockers, calcium channel blockers): may cause excessive blood pressure lowering.
  • CYP450 inhibitors (e.g., fluconazole): possible increase in olmesartan levels.
  • Antacids containing aluminum or magnesium: may affect absorption of olmesartan.
  • Beta‑agonists (e.g., albuterol): may reduce antihypertensive response.

Frequently Asked Questions

Olmesartan Plus Hct Eg is indicated for the treatment of essential hypertension. The combination of an angiotensin II receptor blocker with a thiazide diuretic provides effective blood‑pressure control, especially in patients who need additional diuretic therapy to manage fluid balance.

Olmesartan medoxil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This leads to relaxation of vascular smooth muscle and reduced sodium‑water retention, thereby lowering systemic arterial pressure.

The prescribed dose is determined by the treating physician based on the patient’s blood‑pressure level, renal function, and response to therapy. Clinicians typically start with a low dose and may adjust it to achieve target blood‑pressure goals while monitoring safety parameters.

Olmesartan Plus Hct Eg is contraindicated during the second and third trimesters of pregnancy because of the risk of fetal toxicity. Limited data are available for breastfeeding; therefore, the product should be used only if the potential benefit justifies the possible risk to the infant.

To request Olmesartan Plus Hct Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both drug classes lower blood pressure by interfering with the renin‑angiotensin system. Olmesartan (an ARB) blocks the AT1 receptor, whereas ACE inhibitors prevent angiotensin‑I conversion to angiotensin‑II. ARBs are generally better tolerated with a lower incidence of cough and angioedema, while ACE inhibitors may be preferred when additional renin‑angiotensin blockade is required.

Olmesartan Plus Hct Eg should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

The product is supplied as oral tablets that are swallowed whole with a glass of water. It is taken once daily, preferably at the same time each day, and can be administered with or without food according to the prescriber’s instructions.

Serious adverse events include angioedema, which can threaten the airway, acute kidney injury, severe dehydration, and hyperkalemia. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, sudden loss of kidney function, or symptoms of high potassium such as muscle weakness.

The medication should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any excipients; in those with severe renal impairment; in pregnant women (second and third trimester); and in individuals with significant electrolyte disturbances such as hyperkalemia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT